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Hormonal replacement therapy in an animal model with the genesis of bone disease and explains its use in the
chronic renal failure and ovariectomy: Biochemical and densi- management of hyperparathyroidism, which has been
tometric study. going on for nearly 30 years and which can be conceptu-Background. In spite of estrogen replacement therapy being
ally considered, at least partially, as a form of hormonalextensively used in clinical and experimental studies without
replacement therapy [4]. The administration of 1,25-renal impairment, there are no long-term studies concerning
estrogen replacement in chronic renal failure. dihydroxy vitamin D improves the intestinal calcium ab-
Methods. In this experimental study, six groups of nephrec- sorption, increases both serum calcium levels and urinary
tomized and ovariectomized animals were treated with differ- calcium excretion, and inhibits the secretion of PTH [5].ent doses of 17-estradiol, alone or in combination with
Apart from the three main regulators of bone metabo-calcitriol, to evaluate the effect of these treatments on bone
lism, Ca, P, and calcitriol, there are others factors thatmetabolism.
Results. Biochemical results showed that estrogen alone did can be implicated on bone metabolism. These factors
not have any effect neither on calcium nor on PTH serum are acidosis, aluminium, magnesium, local factors, and
levels. By contrast, in the groups treated with calcitriol, the hormones such as estrogens.
levels of serum calcium were significantly higher, and the levels
Although there have been many clinical and experi-of iPTH were significantly lower than those observed in the
mental studies demonstrating that estrogen reduces bonecontrol group. Animals receiving the combined treatment with
estrogen and calcitriol showed the greater gain in uterus weight loss and fractures in postmenopausal women [6, 7], little
and a better bone mineral density at the lumbar site and the is known about the possible role that estrogen deficiency
proximal and distal tibia sites. plays in the pathogenesis and progression of bone disease
Conclusion. The combination of estrogen and calcitriol is
in chronic renal failure [8].the most effective therapy to prevent bone mass loss in animals
Taking into account the decrease of calcium absorp-with chronic renal failure and estrogen deprivation.
tion and the decrease of the estrogen levels that occur
after menopause, it is likely that the combined therapy
with estrogen and calcitriol has a synergic or additiveBone disease in chronic renal failure is a complex
effect on bone in uremic patients. For this reason, the aimmetabolic disorder. The alterations in bone metabolism
of this study was to evaluate the effect of replacementvary depending on different factors, among which are
treatment with different doses of 17-estradiol (E2),age, sex, cause of renal failure, and, above all, the treat-
alone or combined with calcitriol on bone metabolismment received both in the predialysis and the dialysis
in an experimental model with nephrectomized andphases [1]. Hypocalcemia, a decrease in 1,25-dihydroxy
ovariectomized rats.vitamin D syntheses, and the retention of phosphate
are the most important factors in the development of
secondary hyperparathyroidism [2, 3] and in the trig- METHODS
gering of bone disturbances.
Animals and dietThe deficiency of calcitriol plays an important role in
Six-month-old female Sprague-Dawley rats, with a
mean body weight of 325  32 g, were acclimatized
Key words: estrogens, calcitriol, bone mass. under standard laboratory conditions at 24  2C and
50% to 60% humidity for one week. The rats were al- 2003 by the International Society of Nephrology
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Table 1. Analysis of the different serum biochemical markers in the different treatment groups at the end of the study
CRF  OVX
Reference CRF
normal group (without OVX) Placebo E2-15 E2-45 CT E2–15  CT E2–45  CT
(N  5) (N  4) (N  7) (N  8) (N  5) (N  7) (N  6) (N  7)
Final body weight g 31026 32124 35534 31319a 3339a 35056 32012a 31813a
Urea mg/dL 315 7011 683 7214 656 696 715 7415
Total proteins g/L 71.21.4 681 673 704 685 694 716 744a
Ca mg/dL 110.44 12.00.3 11.80.3 11.70.3 11.60.1a 13.01a 12.60.3a 13.50.8a
P mg/dL 4.80.6 4.80.6 5.70.9 4.70.6a 4.50.8 5.70.9a 5.30.8 6.20.6a
Alkaline phosphatase UI/L 24465 19842 24561 17352a 27184a 20865 22858 9419a
PTH pg/mL 14.86.0 12.42.1 18.77.3 17.39.0 12.13.3 4.12.7a 3.61.2a 9.35.6a
17-E2 pg/mL 45.222.6 32.013.0 12.23.07a 23.613.5a 35.93.3a 12.13.1a 18.99.9 28.76.7a
a P  0.05
lowed free access to tap water and commercial standard and weighed for their use as markers of estrogen replace-
ment.rodent chow containing 0.6% calcium, 0.6% phosphorus,
and 1500 kg of vitamin D3 (Diet A04, Panlab SL, Barce-
Biochemical studieslona, Spain).
Blood was obtained after sacrifice. The serum urea,
Experimental design calcium, phosphorus, and alkaline phosphatase, as well
as the total proteins, were measured using a multi-chan-Chronic renal failure (CRF) was surgically induced
using the technique modified by Ormrod and Miller [9] nel autoanalyzer (Hitachi 717, Boehringer Mannheim,
Berlin, Germany). The serum concentration of N-termi-(equivalent to 7/8 nephrectomy). Estrogen deprivation
was obtained using bilateral ovariectomy (OVX) [10]. nal PTH was measured using a chicken anti-PTH anti-
body (CK67.57) in an IRMA Rat PTH (Inmunotopics,Both procedures were performed in the same surgical
intervention using intraperitoneal ketamine hydrochlo- San Juan Capistrano, CA, USA). Levels of 17-estradiol
were measured by radioimmunoassay (RIA) (Diagnosticride (Ketolar) and medetomidine (Domtor) as anesthe-
tics at dosages of 42 and 0.16 mg/kg, respectively. One Systems Laboratories, Inc., Webster, TX, USA).
week after the surgery, the group with CRFOVX were
Bone mineral measurementsdivided into six treatment groups. Group 1 received the
vehicle (corn oil) at a dose of 0.8 mL/kg body weight Bone mineral density (BMD) was measured by dual-
energy x-ray absorptiometry (DXA; Hologic QDR 100,(BW)/day (N  7) administered daily intraperitoneally
for eight weeks. Group 2 received 17-estradiol (E2) Bedford, MA, USA), adapted to the measurement of
BMD in small animals. These measurements were per-(Sigma Chemical Co., St. Louis, MO, USA) dissolved in
small amounts of ethanol with the volume adjusted with formed in vivo at the lumbar vertebra site, which in-
cluded the first five lumbar vertebrae (using the last ribcorn oil to give a concentration of 15 g/kg/BW/day and
administered daily intraperitoneally for eight weeks (E2  as reference), and ex vivo at the isolated right tibias in
three segments: total, one-eight proximal, and seven-15, N  8). Group 3 received E2 at a dose of 45 g/kg/
BW/day administered daily intraperitoneally for eight eight distal sites, according to Go´mez Alonso et al [11].
weeks (E2  45, N  5). Group 4 received calcitriol
Statistical analysis[1	,25(OH)2D3] (Sigma Chemical Co., St. Louis, MO,
USA) dissolved in small amounts of ethanol with the Statistical analysis was performed using the Mann-
Whitney test as a nonparametric test on SPSS 8.0 soft-volume adjusted with corn oil to give a concentration
of 10 ng/kg/BW/day administered daily intraperitoneally ware for Windows (SPSS, Inc., Chicago, IL, USA). The
results were expressed as mean standard deviation; dif-for eight weeks (N  7). Group 5 received E2  15 in
combination with calcitriol 10 ng/kg/BW, both adminis- ferences were considered significant at a level of P 0.05.
tered daily intraperitoneally for eight weeks (N  6).
Group 6 received E2  45 in combination with calcitriol RESULTS
10 ng/kg/BW, both administered daily intraperitoneally
Biochemical parametersfor eight weeks (N  7). The group with CRF (N  4)
without bilateral ovariectomy was used as the control The analysis of the different biochemical parameters
is shown in Table 1. At the end of the experiment, allgroup. In addition, a group of animals of the same age
without any manipulation (N 5) was used as the normal of the nephrectomized groups had similar serum urea
levels (71  10 mg/dL), which were significantly higherreference group. All rats were sacrificed by exsanguina-
tion after eight weeks, and their uteruses were removed than those observed in the reference group of the same
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Fig. 1. Uterus weight in the different treatment groups. The gray bar
shows the mean standard deviation in the CRF control group. Uterus
weight in the reference normal group was 0.496  0.161 g (N  5).
*P  0.05
age with normal renal function (31  5 mg/dL) (P 
0.001).
The groups treated with calcitriol or with the com-
bined treatment (E2  15  calcitriol and E2  45 
calcitriol) showed serum calcium levels that were signifi-
cantly higher, whereas serum PTH levels were lower
than those observed in the rest of the groups.
In the groups treated with the two doses of E2 tested, Fig. 2. BMD at the lumbar spine and the proximal tibia segment. (A)
alone or in combination with calcitriol, the serum levels The gray bar shows the mean  standard deviation in the CRF control
group. BMD in the reference normal group was 0.269  0.010 g/cm2of 17-estradiol were within the range observed in the
(N  5). *P  0.05. (B) The gray bar shows the mean  standardanimals without ovariectomy (reference and control
deviation in the CRF control group. BMD in the reference normal
group). Furthermore, a proportional increase in the lev- group was 0.363  0.016 g/cm2 (N  5). *P  0.05.
els of 17-estradiol with the dose of E2 tested was ob-
served (Table 1).
The groups treated with E2 alone were able to only
both in the rest of the treatment, control, and referencepartially recover the uterus weight, whereas those
groups (0.27  0.01 vs. 0.25  0.01, P  0.001).treated with calcitriol alone had no effect at this level.
Only the groups treated with E2  calcitriol achieved a
uterus weight close to that of the rats with normal ovarian DISCUSSION
function (Fig. 1).
The analysis of the different markers of estrogen re-
placement and the BMD measurements in our animalBone mineral measurements
model with CRF  OVX showed that the combinedAt the lumbar spine, the BMD values in the placebo
therapy with E2  calcitriol was the most effective strat-group were significantly lower than those observed in
egy in order to prevent the bone mass loss at lumbarthe CRF control group (P  0.05). Treatment with E2
and tibia sites.alone, at any of the doses tested, was not able to recover
Biochemical results showed that in the groups thatthe bone loss that occurred after E2 deprivation. Animals
received calcitriol or the combined treatment with E2 that received calcitriol alone or combined with E2
calcitriol, the levels of serum calcium were significantlyreached BMD values similar to those of the control and
higher, and the levels of PTH were significantly lowerreference groups (Fig. 2).
to those observed in the rest of the groups [5]. It is knownAt the proximal tibia segment, animals treated with
that the anti-resorptive effect of calcitriol is due to aplacebo or with E2 at the lower dose showed low BMD
reduction of secondary hyperparathyroidism, a processvalues. In contrast, animals treated with E2  45, with cal-
that is mediated by the direct effect of the calcitriol oncitriol, or with the combination of both (E2  15 
the gland or by an increase in the intestinal absorptioncalcitriol and E2 45 calcitriol), achieved BMD values
of calcium [5, 12]. E2 alone did not seem to have anythat were within the range observed in the control and
effect neither on calcium nor on PTH serum levels. How-reference groups (Fig. 2).
ever, other studies have reported that E2 has an effectAt the distal tibia segment, only the group treated
with E2  45  calcitriol achieved BMD values higher that increases the intestinal calcium absorption, either
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by a direct action of E2 on renal 1	-hydroxylase [13] nal bone growth, which is in accordance with the fact
that rats do not close the growth plate; however, theor on VDR [14] expression, or indirectly stimulating
1,25(OH)2D renal synthesis through increments in PTH areas of these segments are similar in all groups (data
not shown). Previous studies have demonstrated greaterlevels [13].
The treatment with E2 alone (both doses) was unable effectiveness of this combined treatment on the cortical
bone [25] compared with estrogen replacement alone.to recover the bone loss at the lumbar spine. It could be
argued that the estradiol dose was insufficient; however, This fact seems to demonstrate that the combination of
E2  calcitriol can have a direct effect on cortical bone,the dose of 45 g/kg/day extrapolated to humans can be
considered in the range of normal-high dose [14, 15]. In emphasizing the importance of the E2 dose used, as the
dose of 15 g/kg/day of E2 showed no effects at thiscontrast, treatment with E2 at the dose of 45 g/kg/day
was able to recover the bone loss at the proximal tibia level, neither alone nor combined with calcitriol.
segment. In fact, at the proximal tibia, 45 g/kg/day of In our study, a possible limitation of the beneficial
E2 was able to achieve BMD values similar to that ob- effect of E2 was the fact that the best results were ob-
served in the groups with normal ovarian function. The tained using a dose that could be considered close to the
greater response to E2 observed at the tibia site, com- upper limit range in human replacement therapy [14, 15].
pared with the spine site, could be explained by the Taking into account the risk that estrogen therapy in-
different proportion of cancellous and cortical bone in volves [26, 27], and the pharmacokinetics of E2 in women
these two segments. It has been previously demonstrated with end-stage renal failure [28], the use of lower doses
that there is a greater loss of cancellous bone than of of this hormone would be more advisable. However, in
cortical bone in postmenopausal women [16] and in our study, non-abnormal proliferative effects with nor-
ovariectomized rats [17, 18]. A recent study on post- mal-high doses of E2 were observed in the uteri of these
menopausal women [19] shows the positive effects of E2 animals after two months of treatment. This is a very
therapy on bone density at the lumbar spine using doses important finding, considering that this period of treat-
of 1 mg and 2 mg of E2, which are proportional to the ment in the rat is the equivalent of seven years of treat-
doses tested in our study. This different response in the ment in women. Histomorphometric studies currently
clinical and experimental studies could also be explained being carried out in our laboratory will help us to deter-
by a lesser content of trabecular bone in the rat lumbar mine with more precision the lowest effective dose of
spine than in humans. E2 that should be used in the combined therapy [29].
The animals which had received the combined treat- The results obtained in our experimental model em-
ment with E2  calcitriol, not only had a better BMD phasize the usefulness of a replacement-combined ther-
at the lumbar spine and proximal tibia, but also showed apy of E2  calcitriol in chronic renal failure with estro-
a better uterus weight gain than that observed in rats gen deficiency. Nonetheless, more studies to optimize
which had only received E2, and similar to that observed the lower E2 dose with greater efficiency are necessary
in the groups with normal ovarian function (reference in order to prevent the possible negative effects that
and control groups). This fact could be explained by a the continuous administration of high doses of E2 can
direct action not only of E2, but also of calcitriol, on the involve.
uterus, possibly mediated by its receptor (VDR). In fact,
there are studies that demonstrate the implication of the ACKNOWLEDGMENTS
VDR in growth, bone formation, and female reproduc-
We thank Marı´a Teresa Allende, Teresa Coto, Mercedes Serrano,tion in adult age [20], including immunohistochemic evi- A´ngeles Carcedo, and Carmen Dı´az-Corte for their help. This study
dence of the existence of this receptor in the uterus [21]. was supported by FIS 98/787. Ara´nzazu Rodrı´guez Rodrı´guez was
supported by a grant from the Fundacio´n Renal In˜igo A´lvarez deThese facts support the hypothesis that the combined
Toledo (2001-2002), and by Plan Regional de Investigacio´n del Princi-treatment could have a synergic effect not only on the pado de Asturias through a FICYT research contract (2002–2003).
uterus, but also on other tissues, such as bone, where Thanks to language consultants Covadonga Dı´az Dı´az and Francesca
Pieraccini.the existence of the VDR and estrogen receptors 	 and
 has been proven [22–24]. Reprint requests to Dr. Jorge B. Cannata Andı´a, Servicio de Metabo-
No differences at the distal tibia site after treatment lismo O´seo y Mineral, Instituto Reina Sofı´a de Investigacio´n, C/Julia´n
Claverı´a s/n, 33006 Oviedo, Spain.were observed between the placebo and all of the other
E-mail: metoseo@hca.esgroups that received active drugs (data not shown). This
is most likely explained by the fact that cortical bone is
REFERENCESless affected by the ovariectomy than cancellous bone
1. Couttenye MM, D’Haese PC, Verschoren WJ, et al: Low bone[16, 18]. Animals treated with high doses of E2  cal-
turnover in patients with renal failure. Kidney Int (Suppl 73):S70–citriol had a significantly higher BMD at the distal tibia
76, 1999
site than those observed in the rest of the treatment 2. Locatelli F, Cannata-Andia JB, Drueke TB, et al: Management
of disturbances of calcium and phosphate metabolism in chronicgroups. It could be argued that this is due to a longitudi-
Rodrı´guez-Rodrı´guez et al: Estrogens and chronic renal failure S-61
renal insufficiency, with emphasis on the control of hyperphospha- 17. Kinney JH, Haupt DL, Balooch M, et al: Three-dimensional mor-
phometry of the L6 vertebra in the ovariectomized rat modeltaemia. Nephrol Dial Transplant 17:723–731, 2002
3. Slatopolsky E: The role of calcium, phosphorus and vitamin D of osteoporosis: Biomechanical implications. J Bone Miner Res
15:1981–1991, 2000metabolism in the development of secondary hyperparathyroidism.
Nephrol Dial Transplant 13(Suppl 3):3–8, 1998 18. Kalu DN: Evolution of the pathogenesis of postmenopausal bone
loss. Bone 17:135S–144S, 19954. Slatopolsky E, Brown AJ: Vitamin d analogs for the treatment
of secondary hyperparathyroidism. Blood Purif 20:109–112, 2002 19. Giske LE, Hall G, Rud T, Landgren BM: The effect of 17beta-
estradiol at doses of 0.5, 1 and 2 mg compared with placebo on5. Kanis JA: Vitamin D analogs: From renal bone disease to osteopo-
rosis. Kidney Int (Suppl 73):S77–81, 1999 early postmenopausal bone loss in hysterectomized women. Os-
teoporos Int 13:309–316, 20026. Cauley JA, Zmuda JM, Ensrud KE, et al: Timing of estrogen
replacement therapy for optimal osteoporosis prevention. J Clin 20. Yoshizawa T, Handa Y, Uematsu Y, et al: Mice lacking the
vitamin D receptor exhibit impaired bone formation, uterine hypo-Endocrinol Metab 86:5700–5705, 2001
7. Riggs BL, Khosla S, Melton LJ 3rd: Sex steroids and the con- plasia and growth retardation after weaning. Nat Genet 16:391–396,
1997struction and conservation of the adult skeleton. Endocr Rev
23:279–302, 2002 21. Johnson JA, Grande JP, Roche PC, Kumar R: Immunohisto-
chemical detection and distribution of the 1,25-dihydroxyvitamin8. Holley JL, Schmidt RJ: Hormone replacement therapy in post-
menopausal women with end-stage renal disease: A review of the D3 receptor in rat reproductive tissues. Histochem Cell Biol 105:7–
15, 1996issues. Semin Dial 14:146–149, 2001
9. Ormrod D, Miller T: Experimental uremia. Description of a 22. Braidman IP, Hainey L, Batra G, et al: Localization of estrogen
receptor beta protein expression in adult human bone. J Bonemodel producing varying degrees of stable uremia. Nephron
26:249–254, 1980 Miner Res 16:214–220, 2001
23. Kusec V, Virdi AS, Prince R, Triffitt JT: Localization of estrogen10. Waynforth H: Experimental and Surgical Technique in the Rat.
London, Harcourt Brace Jovanovich, 1980 receptor-alpha in human and rabbit skeletal tissues. J Clin Endocri-
nol Metab 83:2421–2428, 199811. Gomez-Alonso C, Menendez-Rodriguez P, Virgos-Soriano MJ,
et al: Aluminum-induced osteogenesis in osteopenic rats with nor- 24. Langub MC, Reinhardt TA, Horst RL, et al: Characterization
of vitamin D receptor immunoreactivity in human bone cells. Bonemal renal function. Calcif Tissue Int 64:534–541, 1999
12. Coburn JW, Elangovan L: Prevention of metabolic bone disease 27:383–387, 2000
25. Gallagher JC, Fowler SE, Detter JR, Sherman SS: Combinationin the pre-end-stage renal disease setting. J Am Soc Nephrol 9:S71–
77, 1998 treatment with estrogen and calcitriol in the prevention of age-
related bone loss. J Clin Endocrinol Metab 86:3618–3628, 200113. Ten Bolscher M, Netelenbos JC, Barto R, et al: Estrogen regula-
tion of intestinal calcium absorption in the intact and ovariecto- 26. Kenemans P, van Unnik GA, Mijatovic V, van der Mooren MJ:
Perspectives in hormone replacement therapy. Maturitas 38mized adult rat. J Bone Miner Res 14:1197–1202, 1999
14. Liel Y, Shany S, Smirnoff P, Schwartz B: Estrogen increases (Suppl 1):S41–48, 2001
27. Marple JT, MacDougall M: Development of malignancy in the1,25-dihydroxyvitamin D receptors expression and bioresponse in
the rat duodenal mucosa. Endocrinology 140:280–285, 1999 end-stage renal disease patient. Semin Nephrol 13:306–314, 1993
28. Ginsburg ES, Owen WF, Jr, Greenberg LM, et al: Estrogen15. Verhaeghe J, Oloumi G, van Herck E, et al: Effects of long-term
diabetes and/or high-dose 17 beta-estradiol on bone formation, absorption and metabolism in postmenopausal women with end-
stage renal disease. J Clin Endocrinol Metab 81:4414–4417, 1996bone mineral density, and strength in ovariectomized rats. Bone
20:421–428, 1997 29. Naves M, Rodrı´guez-Rodrı´guez A, Dı´az-Corte C, et al: Effect
of estrogen and calcitriol replacement in bone mass in rats with16. Stepan JJ, Pospichal J, Presl J, Pacovsky V: Bone loss and bio-
chemical indices of bone remodeling in surgically induced post- chronic renal failure and ovariectomy. Am J Soc Nephrol 12:746A,
2001menopausal women. Bone 8:279–284, 1987
